Shortened studies favor Big Pharma
Sooner isn’t always better… especially when it comes to drug research.
In fact, drug studies that end early–something that happens more often than you might think–tend to exaggerate the med’s effectiveness and miss dangerous side effects and complications, according to a new report.
Researchers compared 91 studies that were cut short to 424 comparable studies that went the distance, and found that the truncated trials overestimated the study drug’s effectiveness by an average of 30 percent.
In some cases, these shortened studies didn’t just make a drug look more effective than it really was… but also magically turned completely ineffective meds into working drugs, according to the study in the Journal of the American Medical Association.
That’s some parlor trick… but it’s just the research equivalent of smoke and mirrors.
Studies are supposedly cut short only when patients are in danger, or researchers get overwhelmingly convincing evidence of a drug’s effectiveness… but in reality, those latter cases are usually just an early spike in the data.
They know this, by the way. They know it–but still end the study early. After all, that’s how the drug companies that fund most of these researchers like it: Get in, get the result you want, and get out–fast. Shorter trials are cheaper, the drug gets to market faster and they can even switch the placebo patients onto the pricey new med.
And, as an extra bonus, a shortened study is also less likely to reveal any potential problems with the med.
That’s the kind of stock-boosting side effect Big Pharma really likes.
Dr. Victor Montori, author of the new study, called the practice misleading… but he’s being kind. Let’s call this what it really is: a dangerous lie.
These lies can have fatal consequences. For example, a study on beta-blockers was cut short when it found seemingly conclusive evidence that these meds can prevent heart attacks during surgery.
So docs began using them based on that conclusion–and who knows how many lives were lost… because a larger trial later on found that some patients on these meds had significantly higher death rates.
When that happens, we’re well beyond “misleading.”
These trials aren’t cut short by a couple of hours, days or weeks… in some cases, they end years ahead of time. The JUPITER trial on the statin drug Crestor, for example, was cut short by two years.
Two whole years!
It’s like walking out on a movie before the end… and missing the part where the villain rises up and kills the main character.
But this tragic ending wasn’t made by Hollywood. As the new study shows, it was brought to you by Big Pharma.
Posted in House Calls.


